Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL2 | P60568 | 3/20 | 0.47 |
| ▸ | MAP4K1 | Q92918 | 3/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.45 |
| ▸ | CDK2 | P24941 | 2/20 | 0.42 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.42 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.42 |
| ▸ | CDK9 | P50750 | 1/20 | 0.42 |
| ▸ | CLK2 | P49760 | 1/20 | 0.41 |
| ▸ | CLK3 | P49761 | 1/20 | 0.41 |
| ▸ | TNIK | Q9UKE5 | 5/20 | 0.41 |
| ▸ | CLK1 | P49759 | 1/20 | 0.41 |
| ▸ | MAP3K11 | Q16584 | 2/20 | 0.40 |
| ▸ | IKBKB | O14920 | 1/20 | 0.40 |
| ▸ | CHUK | O15111 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | INSR | P06213 | 1/20 | 0.40 |
| ▸ | FLT3 | P36888 | 1/20 | 0.40 |
| ▸ | NTRK1 | P04629 | 4/20 | 0.40 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.40 |
| ▸ | PIM1 | P11309 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30400402 | 0.90 | MAP4K1 (0.58) | IL2MAP4K1DYRK1ACDK2CCNT1 | |
| SCHEMBL26175600 | 0.90 | MAP4K1 (0.58) | IL2MAP4K1DYRK1ACDK2CCNT1 | |
| SCHEMBL30399189 | 0.86 | DYRK1A (0.47) | IL2MAP4K1DYRK1ACDK2CCNT1 | |
| SCHEMBL26177407 | 0.86 | DYRK1A (0.47) | IL2MAP4K1DYRK1ACDK2CCNT1 | |
| SCHEMBL26174832 | 0.84 | CLK1 (0.47) | IL2MAP4K1DYRK1ACDK2CCNT1 | |
| SCHEMBL26175663 | 0.83 | MAP4K1 (0.63) | IL2MAP4K1DYRK1ACDK2CLK2 | |
| SCHEMBL26175331 | 0.81 | PDPK1 (0.52) | — | |
| SCHEMBL26174870 | 0.79 | TNIK (0.50) | MAP4K1CDK2TNIKMAP3K11IKBKB | |
| SCHEMBL26175472 | 0.79 | IL2 (0.59) | IL2MAP4K1DYRK1ACDK2CCNT1 | |
| SCHEMBL26175244 | 0.78 | CDK8 (0.59) | DYRK1ACDK2CCNT1CCNA2CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4415817-A1 | 1H-PYRROLO[2,3-B]PYRIDINES AS DYRK1A INHIBITORS | BioSplice Therapeutics, Inc. (US) | 2024-08-21 | — | — | EP | claimed |
| WO-2023064349-A1 | 1H-PYRROLO[2,3-B]PYRIDINES AS DYRK1A INHIBITORS | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-04-20 | — | — | WO | claimed |
| EP-4415817-A1 | 1H-PYRROLO[2,3-B]PYRIDINES AS DYRK1A INHIBITORS | BioSplice Therapeutics, Inc. (US) | 2024-08-21 | — | — | EP | disclosed |
| US-20230192686-A1 | 1H-PYRROLO[2,3-B]PYRIDINES AND PREPARATION AND USES THEREOF | TENARX, INC. | 2023-06-22 | — | — | US | disclosed |
| US-20230192686-A1 | 1H-PYRROLO[2,3-B]PYRIDINES AND PREPARATION AND USES THEREOF | TENARX, INC. | 2023-06-22 | — | — | US | disclosed |
| WO-2023064349-A1 | 1H-PYRROLO[2,3-B]PYRIDINES AS DYRK1A INHIBITORS | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192686-A1 | 1H-PYRROLO[2,3-B]PYRIDINES AND PREPARATION AND USES THEREOF | DYRK1A, DYRK1B, DYRK2 | IL2 2765/4885MAP4K1 14/4885DYRK1A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.